Literature DB >> 17149595

Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.

Melinda S Merchant1, Fraia Melchionda, Manoj Sinha, Chand Khanna, Lee Helman, Crystal L Mackall.   

Abstract

Primary tumors developing in immunocompetent hosts escape immunosurveillance by acquiring immune evasive properties. This raises the prospect that metastases derived from such tumors will also evade immunity. To investigate whether immune surveillance plays a role in preventing metastases, we studied a murine model which mimics the clinical progression of osteosarcoma: primary tumor growth in the lower extremity, amputation, minimal residual disease followed by the development of overt metastases. K7M2 implants readily escaped immune surveillance since normal BALB/c mice, T cell deficient SCID and T/NK cell deficient SCID-bg mice showed no difference in the rate of growth of primary osteosarcomas. However, both SCID and SCID-bg mice had higher rates of metastases than immunocompetent mice. Similarly, immune reconstitution following transfer of naive T cells to SCID or SCID-bg mice did not impact primary tumor growth, but significantly diminished metastatic recurrence. T cells in osteosarcoma bearing mice produced IFNgamma in response to tumor and IFNgamma production by immune reconstituting T cells was required to prevent metastases. These results demonstrate an important role for T cell based immune surveillance in preventing metastases, even when metastases develop from tumors that adeptly evade immunosurveillance. The results further suggest that T cell depleting cancer therapies may eliminate beneficial immune responses and that immune reconstitution of lymphopenic cancer patients could prevent metastatic recurrence of solid tumors.

Entities:  

Mesh:

Year:  2006        PMID: 17149595     DOI: 10.1007/s00262-006-0257-0

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.

Authors:  Crystal L Mackall; Eunice H Rhee; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; Donna Bernstein; Merertu Tesso; Lauren M Long; David Grindler; Margret Merino; William Kopp; Maria Tsokos; Jay A Berzofsky; Lee J Helman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

2.  Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.

Authors:  Joanna L Meadors; Yonghzi Cui; Qing-Rong Chen; Young K Song; Javed Khan; Glenn Merlino; Maria Tsokos; Rimas J Orentas; Crystal L Mackall
Journal:  Pediatr Blood Cancer       Date:  2011-04-01       Impact factor: 3.167

Review 3.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

4.  Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Authors:  Zhiqiang Xu; Michelle A Hurchla; Hongju Deng; Ozge Uluçkan; Fang Bu; Andrew Berdy; Mark C Eagleton; Emanuela A Heller; Desiree H Floyd; Wessel P Dirksen; Sherry Shu; Yuetsu Tanaka; Soledad A Fernandez; Thomas J Rosol; Katherine N Weilbaecher
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

Review 5.  Immune-based therapeutics for pediatric cancer.

Authors:  Christian M Capitini; Crystal L Mackall; Alan S Wayne
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

6.  Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.

Authors:  Melinda S Merchant; Matthew Wright; Kristin Baird; Leonard H Wexler; Carlos Rodriguez-Galindo; Donna Bernstein; Cindy Delbrook; Maya Lodish; Rachel Bishop; Jedd D Wolchok; Howard Streicher; Crystal L Mackall
Journal:  Clin Cancer Res       Date:  2015-11-03       Impact factor: 12.531

7.  Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.

Authors:  Melinda S Merchant; Donna Bernstein; Martha Amoako; Kristin Baird; Thomas A Fleisher; Michel Morre; Seth M Steinberg; Marianna Sabatino; Dave F Stroncek; Aradhana M Venkatasan; Bradford J Wood; Matthew Wright; Hua Zhang; Crystal L Mackall
Journal:  Clin Cancer Res       Date:  2016-01-28       Impact factor: 12.531

8.  Bioinformatics analysis of differentially expressed pathways related to the metastatic characteristics of osteosarcoma.

Authors:  Wei Sun; Xiaojun Ma; Jiakang Shen; Fei Yin; Chongren Wang; Zhengdong Cai
Journal:  Int J Mol Med       Date:  2016-06-27       Impact factor: 4.101

9.  Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients.

Authors:  Pooja Hingorani; Mary L Maas; Michael P Gustafson; Paul Dickman; Roberta H Adams; Masayo Watanabe; Francis Eshun; James Williams; Matthew J Seidel; Allan B Dietz
Journal:  J Immunother Cancer       Date:  2015-08-18       Impact factor: 13.751

10.  Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.

Authors:  Binghao Li; Xiaobing Zhu; Lingling Sun; Li Yuan; Jian Zhang; Hengyuan Li; Zhaoming Ye
Journal:  Oncotarget       Date:  2014-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.